|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Relationship between the Methylation of Promoter Regions of Tumor Suppressor Genes PTEN and APC with Endometrial Cancer.
|
31450893 |
2019 |
|
Malignant neoplasm of endometrium
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of expression of PTEN gene may turn out to be a very useful tool aimed at qualifying patients for different therapies of endometrial cancer and at searching of new diagnostic and therapeutic methods of this cancer independently on its receptor status nor maturity grade of cancer.
|
24030769 |
2014 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Concomitant loss of PTEN expression and PIK3CA mutation was found in four cases of endometrial cancer.
|
18221484 |
2009 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
|
30569174 |
2019 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancer patients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer.
|
22146979 |
2012 |
|
Malignant neoplasm of endometrium
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, it appears that tamoxifen-associated endometrial cancers are not significantly different from sporadic endometrial cancer with regards to PTEN IHC expression, although there is a trend towards retained PTEN expression.
|
12530022 |
2003 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Adding PTEN/TP53 mutation testing to BHLHE22/CDO1-based methylation testing did not improve the detection of endometrial cancer.
|
31779688 |
2019 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although these data do not preclude the possibility of an increased risk of endometrial cancer in association with the Cowden syndrome, they indicate that germline PTEN mutations do not account for a significant proportion of genetic attributable risk for endometrial carcinoma.
|
15589575 |
2005 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
TTF-1 and PTEN can be used as molecular markers for the early diagnosis of endometrial cancer, which are closely related to clinical features and may affect tumor progression by regulating the proliferation activity of tumor cells.
|
28745797 |
2017 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proliferation, transwell and apoptosis assay suggested that MDH2 enhanced the proliferation, migration and invasion but inhibited the apoptosis of endometrial cancer cell line through suppressing PTEN.
|
28189066 |
2017 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model.
|
25461816 |
2015 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using endometrial cancer cellular models with known PTEN status, we evaluated their homologous recombination (HR) functionality by RAD51 foci formation assay.
|
28886696 |
2017 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of ABTL0812 on proliferation, cell death and modulation of intracellular signaling pathways in a wide panel of endometrioid and non-endometrioid cell lines, an inducible PTEN knock-out murine model, and two patient-derived xenograft murine models of EC.
|
30853360 |
2019 |
|
Malignant neoplasm of endometrium
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To test the hypothesis that insulin signalling plays a key role in the development of EC in women with PCOS by measuring and comparing the expression of three key genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in endometrial tissue obtained from three groups of women; PCOS without EC, women with EC without PCOS and non-PCOS women without EC (controls).
|
26802879 |
2016 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies in cell cultures have demonstrated that histone deacetylase inhibitors exert their antineoplastic activity by promoting expression of p21WAF1 and p27KIP1, cyclin-dependent kinase inhibitors, that have important roles in cell cycle regulation; importantly, the transcription of specific genes (e.g., E-cadherin, PTEN) that are commonly silenced in endometrial cancer is also enhanced.
|
29509243 |
2018 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sequencing analysis of entire coding region of PTEN/MMAC1 gene revealed mutations in three of six endometrial cancer cell lines (50%) and 17 of 44 endometrial cancer tissues (39%).
|
10657903 |
2000 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
For example, PTEN/AKT pathway and its downstream targets and the mTOR (mammalian target of rapamycin) pathway have been shown to play an important role in endometrial cancer pathogenesis.
|
21495229 |
2010 |
|
Malignant neoplasm of endometrium
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated a high variability of individual endometrial cancer samples in the levels of PTEN.
|
29477866 |
2018 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we analyzed mutations in 11 cancer-related genes with mononucleotide repeats susceptible to MSI in a coding region [hMSH3 (A8), hMSH6 (C8), TGF-beta RII (A10), MBD4 (A10), BAX (G8), PTEN (A6 in exon 7), HDAC2 (A9), EPHB2 (A9), Caspase-5 (A10), TCF-4 (A9) and Axin2 (G7)] in 22 patients with MSI-H sporadic endometrial cancer.
|
19787250 |
2009 |
|
Malignant neoplasm of endometrium
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study.
|
31348233 |
2019 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
Enhanced cell growth inhibition following PTEN nonviral gene transfer using polyethylenimine and photochemical internalization in endometrial cancer cells.
|
15453811 |
2004 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated gene transfer was carried out using Ishikawa 3 H 12 and RL95-2, the endometrial cancer cell lines with completely inactivated PTEN, together with endometrial cancer cell lines HEC1-A and KLE expressing wild-type PTEN as the control.
|
10568810 |
1999 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest the impact of PTEN loss on tumor biology and clinical outcomes must be interpreted in the context of body mass index, and provide a potential explanation for discrepant reports on the effect of PTEN status and obesity on prognosis in endometrial cancer.
|
26045339 |
2015 |
|
Malignant neoplasm of endometrium
|
0.600 |
Biomarker
|
disease |
BEFREE |
MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells.
|
24929707 |
2014 |
|
Malignant neoplasm of endometrium
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Three different human endometrial cancer cell lines known to have wild-type PTEN (HEC 1-A) or a mutated inactive PTEN protein (RL 95-2 and Ishikawa) were used for these studies.
|
15067356 |
2004 |